

**REMARKS**

The amendment to claim 29 is supported by the specification, page 11, line 10. New claim 35 is supported by claim 29. Claims 17 and 20-35 are now pending. No new matter has been added.

Attached herewith is a marked-up version of the changes made to the claims by this amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,



\_\_\_\_\_  
Jonathan P. Taylor, Ph.D.  
Registration No. 48,338  
Agent for Applicant

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, ILLINOIS 60610  
(312) 321-4200

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

29. (Amended) The injectable formulation of claim 28, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), an anti-vascular endothelial growth factor Fab (anti-VEGF Fab), a [glucagons] glucagon-like peptide I (GLP-I), a nerve growth factor, [and] an insulin-like growth factor, and an antibody.